Drug Administration Law of the People's Republic of China

Drug Administration Law of the People's Republic of China
Name	Drug Administration Law of the People's Republic of China
Enacted	2019 (amended 2021)
Jurisdiction	People's Republic of China
Status	In force

Drug Administration Law of the People's Republic of China is a primary statutory framework governing pharmaceuticals, traditional medicines, and related biological products within the People's Republic of China. The law consolidates safety, efficacy, quality, and supervision obligations across research, production, distribution, and post-marketing stages, interacting with administrative agencies such as the State Council, the National Medical Products Administration, and provincial health authorities. It supersedes earlier regulations and aligns Chinese practice with international instruments like the International Council for Harmonisation guidelines and bilateral regulatory dialogues involving the European Union and the United States Food and Drug Administration.

Background and Legislative History

The law emerged from legislative reform efforts following public incidents and regulatory modernization initiatives linked to institutions such as the Supreme People's Court and the National People's Congress. Initial trajectories trace to regulatory frameworks administered by the China Food and Drug Administration and the later establishment of the National Medical Products Administration under the State Council reorganization. High-profile events involving companies like Changsheng Biotechnology and recalls influenced amendments debated in sessions of the Standing Committee of the National People's Congress and consultations with academic bodies including the Chinese Academy of Sciences and the Peking University Health Science Center. International comparisons to statutes in the United Kingdom, Japan, and Australia informed provisions on liability and market access, while cooperation with the World Health Organization shaped pharmacovigilance expectations.

Scope and Key Definitions

The statute delineates its reach over chemical drugs, traditional Chinese medicines, biological products, vaccines, and medical devices under intersecting law such as the Vaccine Administration Law of the People's Republic of China. Definitions borrow terminology familiar to regulators like the European Medicines Agency, specifying "drug" categories, "manufacture", "distribution", "registration", and "adverse reactions". It clarifies distinctions among entities such as pharmaceutical enterprises, research institutions like the Chinese Academy of Medical Sciences, and market authorization holders, aligning nomenclature with codes used by the World Trade Organization and customs authorities such as the General Administration of Customs of the People's Republic of China.

Regulatory Authorities and Institutional Framework

Primary enforcement responsibilities rest with the National Medical Products Administration, provincial market supervision bureaus, and municipal health commissions, coordinated under executive direction from the State Council. Judicial review and civil remedies involve the Supreme People's Court and local courts, while administrative reconsideration appeals may proceed through the Ministry of Justice. Scientific advisory functions are undertaken by expert committees convened from institutions like the Chinese Center for Disease Control and Prevention, Tsinghua University, and the Shanghai Institute of Materia Medica. Cross-sector cooperation features the National Health Commission, the National Development and Reform Commission, and international liaison with agencies such as the Pharmaceuticals and Medical Devices Agency of Japan.

Drug Approval and Registration Procedures

The law prescribes market authorization pathways, technical dossier requirements, and clinical trial oversight, integrating standards from the International Council for Harmonisation and practice in regulatory jurisdictions like the United States Food and Drug Administration. Applicants must submit data on quality, safety, and efficacy to the National Medical Products Administration or delegated provincial authorities, with expedited channels for breakthrough therapies similar to mechanisms used by the European Medicines Agency and the Food and Drug Administration. Clinical trials require approval from ethics committees referenced to models in the Helsinki Declaration and oversight from institutions such as the Chinese Clinical Trial Registry. Provisions address registration renewals, changes, and withdrawals, reflecting obligations under trade frameworks including the World Trade Organization agreements.

Manufacturing, Distribution, and Quality Control Requirements

Manufacturing facilities must meet Good Manufacturing Practice standards compatible with those in United States Pharmacopeia and European Pharmacopoeia, inspected by the National Medical Products Administration and provincial inspection teams. Quality management systems, batch release, cold chain logistics for products like vaccines overseen by the National Health Commission, and serialization requirements echo global supply chain practices involving customs bodies like the General Administration of Customs of the People's Republic of China. Distributors and pharmacies—regulated entities analogous to licensed establishments in the United Kingdom and Germany—must maintain records, storage conditions, and traceability, while traditional medicine producers coordinate with research centers such as the China Academy of Chinese Medical Sciences.

Safety Monitoring, Pharmacovigilance, and Adverse Event Reporting

Post-marketing surveillance obligations mandate adverse event reporting to a national pharmacovigilance system administered by the National Medical Products Administration and supported by the Chinese Center for Disease Control and Prevention. The law requires marketing authorization holders and healthcare institutions—such as hospitals affiliated with Peking Union Medical College Hospital—to report signals, implement risk mitigation, and communicate safety information consistent with processes used by the World Health Organization and regional regulators like the European Medicines Agency. Requirements include periodic safety update reports, risk management plans inspired by practices at the Food and Drug Administration, and mechanisms for safety-linked recall coordination with provincial market supervision bureaus.

Enforcement, Inspections, and Legal Liability

Enforcement tools include administrative penalties, license revocation, criminal referrals to procuratorates, and civil liability adjudicated by courts such as the Beijing No.1 Intermediate People's Court; precedents from cases involving major corporations and judicial interpretations by the Supreme People's Court shape remedies. Inspection authorities conduct planned and surprise audits, coordinate with anti-corruption bodies like the Central Commission for Discipline Inspection when misconduct intersects with public office, and may impose fines or order cessation under standards comparable to enforcement in Canada and Australia. The law enhances whistleblower protections and consumer rights interfaces with agencies such as the State Administration for Market Regulation and provides pathways for product recalls and compensation adjudication through local courts and administrative mediation panels.

Category:Pharmaceutical law of China